Evidence map›Paper›PMID 41071738›Full record

ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2025

Inclusion of Women, Children, the Elderly, and Individuals With Underlying Medical Conditions: Prioritizing Vulnerable Populations in Clinical Research.

Katia J Bruxvoort, Hannah Bahakel, Judith M Martin, Jennifer L Nayak, Stephanie L Rolsma, C Mary Healy, C Buddy Creech

Abstract read
In one paragraph

Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Katia J BruxvoortSchool of Public Health, University of Alabama, Birmingham, Alabama, USA.ORCID 0000-0001-8277-2431
Hannah BahakelDepartment of Pediatrics, Division of Infectious Diseases, Cincinnati Children's Hospital and Medical Center ; Cincinnati, Ohio, USA.ORCID 0000-0001-9246-5662
Judith M MartinDepartment of Pediatrics, University of Pittsburgh Medical Center ; Pittsburgh, Pennsylvania, USA.ORCID 0000-0001-9456-1770
Jennifer L NayakDepartment of Pediatrics, Division of Pediatric Infectious Diseases, University of Rochester Medical Center ; Rochester, New York, USA.
Stephanie L RolsmaVanderbilt Vaccine Research Program, Department of Pediatrics, Vanderbilt University Medical Center ; Nashville, Tennessee, USA.ORCID 0000-0002-7636-2222
C Mary HealyDepartment of Pediatrics, Division of Pediatric Infectious Diseases, Baylor College of Medicine ; Houston, Texas, USA.
C Buddy CreechVanderbilt Vaccine Research Program, Department of Pediatrics, Vanderbilt University Medical Center ; Nashville, Tennessee, USA.

Funding

Leadership Group for the Infectious Diseases Clinical Research Consortium (IDCRCLG) - Momi-Vax DMID #21-0004 {Supplement #6}UM1AI148684 · NIAID · EMORY UNIVERSITY · PI DAVID S STEPHENS · 2020 to 2026
$77.2M
Vanderbilt Vaccine and Treatment Evaluation Unit - KidCOVEUM1AI148452 · NIAID · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Clarence Buddy Creech · 2020 to 2026
$51.3M
Infectious Diseases Clinical Research ConsortiumNational Institute of Allergy and Infectious DiseasesNIAID NIH HHS UM1 AI148452NIAID NIH HHS UM1 AI148684NIH HHS UM1AI148684
6 · The paper itself

Abstract

For over 60 years, the National Institutes of Health (NIH)-funded Vaccine and Treatment Evaluation Units (VTEUs) have led national efforts in vaccine development, evaluation of novel treatment of infectious diseases, and pandemic preparedness. Although most VTEU research has been conducted in healthy adult volunteers, the VTEU is composed of specialized clinician-scientists in pediatrics, maternal fetal medicine, and specialties that care for immunocompromised hosts. Here we summarize the role of the VTEU in the investigation of the safety and efficacy of vaccines and therapeutics in vulnerable populations, including children, pregnant women, the elderly, and immunocompromised individuals.

Indexed as

Biomedical ResearchVulnerable PopulationsAdultAgedChildFemaleHumansImmunocompromised HostNational Institutes of Health (U.S.)PregnancyUnited StatesVaccinesVaccinesclinical researchpediatric researchvaccinesvaccinologyvulnerable populations

Identifiers

PMID41071738
PMCPMC12513348

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.